These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698 [TBL] [Abstract][Full Text] [Related]
11. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors. Jecrois ES; Zheng W; Bornhorst M; Li Y; Treisman DM; Muguyo D; Huynh S; Andrew SF; Wang Y; Jiang J; Pierce BR; Mao H; Krause MK; Friend A; Nadal-Nicolas F; Stasheff SF; Li W; Zong H; Packer RJ; Zhu Y Dev Cell; 2021 Oct; 56(20):2871-2885.e6. PubMed ID: 34428430 [TBL] [Abstract][Full Text] [Related]
12. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Su W; Xing R; Guha A; Gutmann DH; Sherman LS Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023 [TBL] [Abstract][Full Text] [Related]
18. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Kim KY; Ju WK; Hegedus B; Gutmann DH; Ellisman MH Neuroscience; 2010 Sep; 170(1):178-88. PubMed ID: 20600672 [TBL] [Abstract][Full Text] [Related]
19. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. Freret ME; Gutmann DH J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429 [TBL] [Abstract][Full Text] [Related]